經濟部
Ministry of Economic Affairs

2025 Big Health

Key Industries in Taiwan

Smart Healthcare, Biotech and Pharmaceuticals, and Sports Technology

2025

Big Health

Key Industries in Taiwan

1 Policy Guidelines

The Big Health Industry is an integration of medical services, health management, fitness and nutrition, and smart technology, and its scope encompasses prevention, diagnosis and treatment, rehabilitation, and wellness. In 2024, the government established the Healthy Taiwan Promotion Committee and launched the Healthy Taiwan Sprout Project to promote healthy living for all, enhance care across all age groups, and improve healthcare efficiency through smart technology. These efforts aim to advance personalized health services and position Taiwan as a global hub for smart healthcare innovation.

To promote a “Healthy Taiwan,” the government has adopted three core strategies. First, it seeks to deepen public-private partnerships (PPPs) to respond proactively and swiftly to industry needs, breaking away from the traditional model in which the government follows passively behind private sector progress.

Second, it is strengthening industry competitiveness by making large-scale investments in AI infrastructure to drive continuous innovation. Third, Taiwan is leveraging its diverse population of 23 million people as a rich database to build a global testbed for emerging health technologies. Once local innovations are market-ready, they can be rapidly introduced to the global market, amplifying both economic and social impact.

Through cross-ministerial collaboration, Taiwan has cultivated a robust biomedical ecosystem. Key developments include improvements in the regulatory environment, growth of biomedical industry clusters, advancements in pharmaceutical and medical device innovation, and the development of pandemic-response technologies. These efforts have earned international recognition. Notably, Taiwan has ranked No. 1 globally for seven consecutive years (2019–2025) in both Numbeo's Global Health Care Index by Country and Health Care Expenditure Index. In terms of market performance, listed and emerging biotech and healthcare companies in Taiwan achieved combined revenues of NT$335.3 billion in 2024, a 7.7% increase over 2023 and the second-highest in the past five years. Looking ahead, Taiwan offers significant long-term growth potential. For international companies, the market's scalability and the maturity of the local supply chain highlight Taiwan's strong appeal as an investment destination.

2 Industry Overview

As global health demands evolve, Taiwan's Big Health Industry has formed around three core pillars: Smart Healthcare, Biotech and Pharmaceuticals, and Sports Technology. These sectors together form a comprehensive care continuum that spans prevention, diagnosis, rehabilitation, and wellness. Driven by technological innovation and policy support, this emerging health economy is fostering cross-sector integration and collaborative development. To further strengthen the Big Health Industry, the government actively encourages enterprises to leverage AI, ICT, and biomedical data technologies. By aligning these with clinical applications, telemedicine, and global markets, Taiwan aims to cultivate localized industrial clusters that are internationally competitive.



(A) Overview of Taiwan's Smart Healthcare Industry

Taiwan's smart healthcare sector has grown rapidly, supported by strong technology integration and clinical application capabilities. A complete, internationally competitive industry chain has emerged, built on three main advantages:

1. Robust Healthcare Infrastructure

Taiwan's well-developed medical system has enabled smart healthcare to evolve from isolated technologies into integrated, cross-sector systems. AI diagnostic imaging platforms and home-based telehealth are now widely used for elder and chronic care.

2. Supportive Policies and Data Infrastructure

The government has eased cross-regional access to electronic medical records, adopted international data standards, and established three AI centers for smart healthcare. These efforts have laid the groundwork for broader medical AI adoption.

3. Diverse Innovation Ecosystem

Cross-sector collaboration among industry, academia, and healthcare providers is accelerating clinical validation of new technologies, supported by strong commercialization and incubation platforms. With advances in generative AI and IoT, smart healthcare is moving toward personalized, real-time care. Taiwan has built a full development ecosystem—from R&D and clinical trials to policy sandboxes and commercialization—to support continued growth.

(B) Overview of the Biotech and Pharmaceutical Industry

Taiwan's biotech and pharmaceutical industry has evolved over the past three decades through consistent policy support, academia–industry collaboration, and technological advancement. The sector now boasts strong innovation capabilities and robust international partnerships. It spans a wide range of fields, including Western pharmaceuticals, Active Pharmaceutical Ingredients (APIs), generics, specialty drugs, biologics, monoclonal antibodies, nucleic acid therapies, cell therapies, and CDMO services. The industry is characterized by high technical density, a diversified product mix, and strong export orientation. Despite the relatively small domestic market, Taiwan continues to attract major pharmaceutical companies and investors from the US, Japan, and the EU, thanks to its transparent regulations, efficient clinical trials, and stable manufacturing quality.

1. Robust Supply Chain and R&D Capacity

Western pharmaceuticals account for over half of domestic revenues. Stable generic exports support legacy firms like YUNGSHIN, TBC, CCPC, and TTY. Innovative new drugs, such as PharmaEssentia's Ropeginterferon alfa-2b (approved in the US and Europe), demonstrate Taiwan's growing success in global markets.

2. Cross-Disciplinary Innovation

Taiwanese companies like Medigen Vaccine Biologics (MVC) and Mycenax Biotech (MYCENAX) are actively developing mRNA, cell therapies, and protein-based biologics through international collaborations. ADCs and RNA therapeutics are moving toward commercialization for cancer, rare diseases, and viral infections.

3. CDMO and Smart Manufacturing

As global pharma increasingly outsources production, Taiwan's CDMO firms—known for flexible processes, regulatory compliance, and quality control—have become attractive partners. ScinoPharm, for example, collaborates with Baxter on API and formulation in Europe, while TaiMed has built a high-end manufacturing plant, reinforcing Taiwan's role as a key CDMO and smart pharma hub in Asia.

(C) Overview of the Sports Technology

Taiwan's sports technology industry is entering a new era, integrating sensor technology, intelligent connectivity, and health-focused applications. The pandemic accelerated global interest in home fitness, remote training, and preventive healthcare, driving the digital and smart transformation of Taiwan's fitness industry. As the world's second-largest exporter of fitness equipment, Taiwan already has a strong foundation in hardware manufacturing, mechanical design, and global distribution. In recent years, under policy support and industrial transformation pressure, the sector has begun adopting AIoT, wearable sensors, personal exercise data cloud platforms, and rehabilitation technologies—creating a dynamic ecosystem that fuses sports, health, and technology.

1. Rising Demand Driving Diverse Applications

The global sports tech market is expected to grow by nearly US$30 billion between 2022 and 2027. Smart fitness applications are expanding across four key domains. First, commercial gyms and fitness centers are adopting equipment that tracks training intensity, movement patterns, and cardiopulmonary responses, enhancing both member engagement and training assessment. Second, home fitness solutions now integrate apps, live-streamed classes, and virtual coaching to address training interruptions caused by the pandemic and geographic limitations. Third, medical and long-term care settings are repurposing fitness equipment for functional training and rehabilitation, helping older adults and post-surgical patients maintain health and quality of life. Fourth, in competitive sports science, smart technology is used to analyze and optimize athlete performance, supporting national training centers and professional teams.

2. Startups and ICT Cross-Sector Collaboration

Startups and ICT players are fueling the industry's transformation. Companies like MOOVO MOBILITY and KeepTossingLab integrate image recognition, electromyography, and AI training models to develop smart mirrors, motion-tracking cameras, and VR fitness tools that transcend traditional space limitations. Traditional medical and industrial tech players are also entering the sports tech space. For example, INTAI has expanded into rehabilitation and assistive training equipment, partnering with hospitals and elder care facilities to validate new solutions in real-world settings and meet growing demand in the aging health market.

(D) Taiwan's Advantage

Smart Healthcare – An Innovative Ecosystem Fueled by Rich Medical Data and ICT Integration

Taiwan is one of the most active countries in medical AI development. According to Newsweek's 2025 ranking of The World's Best Smart Hospitals, eight Taiwanese hospitals made the list—giving Taiwan the highest density of smart hospitals in Asia. Strong government support, a robust healthcare and tech sector, vast data resources, and a highly skilled workforce together form the foundation of Taiwan's smart healthcare advantage. As global demand for telemedicine and elderly care continues to grow, Taiwan is well positioned to become a hub for exporting smart healthcare technologies and applications across Asia.

(1) A Complete AI Industry Ecosystem

As of 2025, Taiwan has over 50 medical AI devices approved by the TFDA, covering applications such as CT imaging, oral cancer screening, cardiac arrest prediction, and automated shift handover records. With support from 23 medical centers, high-performance computing infrastructure, and leading tech companies like Acer, ASUS, and Quanta, Taiwan has built a robust AI healthcare pipeline from R&D to commercialization. Government funding and flexible regulation further accelerate clinical deployment.

(2) Strong ICT Integration Capabilities

Taiwan's comprehensive semiconductor and ICT supply chain enables rapid development of healthcare-driven solutions. Foxconn has collaborated with Kawasaki (Japan), NVIDIA (US), and Taichung Veterans General Hospital to develop Nurabot, an AI-powered nursing robot integrating digital twin technology and smart hospital systems—demonstrating Taiwan's strength in healthcare innovation.

(3) Abundant Medical Data Resources

Taiwan's National Health Insurance database offers comprehensive, high-quality medical data for AI training and disease prediction. Through open data initiatives, de-identification technology, AI platform development, and international partnerships, Taiwan promotes medical decision-making, AI innovation, and pandemic preparedness—establishing itself as a key global partner in smart healthcare collaboration and research.

Biotech and Pharmaceuticals – A Hub for Global Collaboration and Accelerated R&D

Taiwan's biotech and pharmaceutical industry has developed a robust R&D ecosystem and industrial infrastructure through years of policy support. Local companies not only innovate in-house but also serve as partners for technology transfer from academia and the adoption of cutting-edge global technologies for future commercialization. With ample funding, skilled talent, and internationally aligned regulatory frameworks, Taiwan continues to see growth in drug approvals and licensing deals. As the CDMO sector grows, Taiwan is emerging as a preferred destination for global pharmaceutical firms seeking R&D acceleration and technical collaboration.

(1) Comprehensive, Flexible Ecosystem with Regulatory Support

Taiwan offers a complete value chain—from R&D and clinical trials to regulatory review, IP protection, mass production, and commercialization—supported by a strong innovation network. Government policies have encouraged expansion into frontier fields such as cell therapy, gene editing, nucleic acid drugs, and digital health. The Ministry of Health and Welfare and the Taiwan FDA have also promoted accelerated reviews, significantly improving approval timelines for new drugs and medical devices. Taiwan now stands as one of Asia's few innovation hubs aligned with global regulatory frameworks.

(2) World-Class CDMO Capabilities with Global Quality Standards

Taiwan's mature CDMO industry offers one-stop services from APIs and formulations to analysis and packaging. Leading players like EirGenix, Formosa Laboratories, and Mycenax have joined the supply chains of US FDA and EU EMA-certified products, securing international contracts. To meet rising demand for nucleic acid and antibody-based therapies, CDMOs are expanding parenteral drugs (sterile injectables) and cell therapy production lines, integrating automation and smart manufacturing to enhance global competitiveness. The government has also prioritized CDMO investment, reinforcing Taiwan's position in the global biotech supply chain.

(3) Precision Medicine and Innovation-Driven R&D

Taiwan has built an efficient translational R&D system, supported by a comprehensive clinical trial platform, genomic databases, and high-quality health insurance data. Top institutions like NTU Hospital, Chang Gung Memorial, and NHRI are advancing research in cancer immunotherapy, nucleic acid drugs, CAR-T therapies, and companion diagnostics, integrating AI and bioinformatics to accelerate drug development. Local firms such as OBI Pharma, BIONET, and Taiwan Liposome Company (TLC) are progressing innovative drug candidates through clinical trials and global licensing, demonstrating Taiwan's ability to rapidly turn research into market-ready products.

Sports Technology – Strong Capabilities in Integrated Hardware and Software

Taiwan's sports technology industry benefits from a highly integrated mechanical and electronics supply chain, enabling rapid mass production of precision sensors and composite-material components. Its robust ICT infrastructure and AI modeling capabilities support the development and optimization of sports data platforms. In addition, Taiwan's comprehensive healthcare and long-term care systems offer real-world testing grounds for healthy aging technologies. As global trends increasingly favor the convergence of sports medicine, rehabilitation technology, and health insurance, Taiwanese companies are well positioned to expand into international markets and deliver diversified services.

(1) Global Supply Chain Capabilities

In 2024, Taiwan's exports of sports equipment totaled approximately US$33.42 billion, with fitness equipment accounting for the largest share. This includes treadmills, elliptical trainers, and weight machines, primarily exported to North America, Europe, and ASEAN countries. Leading manufacturers such as Johnson Health Tech, Dyaco International, and Rexon Industrial provide OEM/ODM services for major international brands, including ICON (US), Technogym (Italy), and Peloton (US). In recent years, these firms have expanded into proprietary branding, integrated content platforms, and built cloud-based fitness ecosystems to meet the evolving needs of global partners and end markets.

(2) Comprehensive Data Infrastructure and Real-World Testing Ecosystem

Taiwan's sports tech industry stands out not only for its advanced manufacturing and R&D environment, but also for its open innovation ecosystem that supports field testing, data collection, and product customization. International companies can collaborate with local partners through OEM/ODM models, co-develop smart sensing and exercise platform modules, or invest directly by establishing regional headquarters or production facilities as a launchpad for further access to ASEAN and Indian markets. With government support via an online platform to promote digital health investments and the ASPN Sports Tech Accelerator, Taiwan reduces barriers to entry and allows companies to quickly gain a competitive edge in the Asia-Pacific health tech market.

(E) Major Industry Clusters Across the North, Central, and South of Taiwan

1. National Biotechnology Research Park (NBRP)

NBRP is Taiwan's first inter-ministerial biotechnology R&D hub, jointly promoted by the Executive Yuan and key government agencies. Positioned as a national-level biotech park with innovation at its core, it brings together institutions such as Academia Sinica, the Ministry of Economic Affairs, and the Ministry of Health and Welfare to foster a collaborative ecosystem of industry, government, academia, and research. Currently home to 47 biotech R&D companies spanning new drug development, medical devices, and AI healthcare, the park continues to attract international pharmaceutical firms to establish R&D centers, solidifying its role as a vital center for biotech innovation in Taiwan.

2. Taipei Bioinnovation Park

Focusing on biotech incubation, clinical trials, and pilot production, Taipei Bioinnovation Park leverages the foundational research strengths of Academia Sinica, the new drug discovery and preclinical R&D capabilities of the adjacent National Biotechnology Research Park, and the new drug review resources of the Taiwan FDA. Together, they form a complete biomedical industry chain in the Nangang area. To date, 51 companies have been approved to enter the park, covering a wide range of fields including biopharmaceuticals, cell therapy, smart health, advanced medical devices, and biotech services. The park enhances the innovation momentum and development depth of the northern Taiwan biotech cluster.

3. Hsinchu Biomedical Science Park (HBSP)

Located near the Hsinchu Science Park, HBSP integrates biomedical R&D, incubation, and clinical applications. It comprises three key units: the Biomedical Science and Product R&D Center, the Industrial and Incubation Center, and the Hsinchu Biomedical Science Park Hospital affiliated with National Taiwan University, providing one-stop R&D and clinical validation platforms. Around 80 companies have established a presence in the park, including firms focused on smart medical devices and biomedical chips, such as PharmaEngine, Synmosa, and Formosa Laboratories, as well as microfluidics and high-tech biomedical chip startups. HBSP is accelerating the growth of the biomedical cluster in northern and central Taiwan.

4. Precision Machinery and Optical Industry Clusters at the Central Taiwan Science Park

The Central Taiwan Science Park is actively integrating emerging technologies such as AI, big data analytics, and cell therapy to drive the development of medical devices, smart manufacturing, and advanced pharmaceutical equipment. Key focus areas include precision diagnostic instruments and intelligent surgical assistive devices. The park's incubation center also supports startups in smart medical technologies. Leveraging Taichung's strengths in precision machining and automation, the cluster continues to expand its scope in smart medical device manufacturing and applications in smart healthcare.

5. Sports-Equipment Industry Cluster in Central Taiwan

The sports equipment cluster in central Taiwan—centered in Taichung—has become a global hub for both manufacturing and brand development. The region leads in the production of bicycles and sports gear, accounting for 53% of Taiwan's total bicycle output and 38% of its sports equipment output. As the market evolves, the cluster is shifting toward integrated technology solutions, home fitness, and health-oriented experiences, demonstrating strong potential for industry transformation.

6. Precision-Health Industry Cluster at the Southern Taiwan Science Park

The Southern Taiwan Science Park is no longer solely focused on semiconductors and optoelectronics, but has become a key biomedical hub in southern Taiwan. The Tainan campus specializes in pharmaceuticals and biotech R&D; Kaohsiung focuses on advanced dental and orthopedic medical devices; Chiayi develops smart healthcare and botanical drugs; Ciaotou is building capacity in biosimilars; and Pingtung targets veterinary and agricultural biologics. Together, these campuses form an integrated network that connects biomedical resources across southern Taiwan and drives medical technology exports.

3 Opportunities for Foreign Investment

A Regulatory Alignment with International Standards

Taiwan now permits cloud-based medical records and mandates global standards like LOINC, ICD-10, and FHIR. In 2024, the National Health Insurance Administration expanded telemedicine reimbursement, while the Ministry of Health and Welfare introduced AI-specific medical regulations. A pilot FHIR data exchange platform was launched with three major medical centers. In 2025, the Ministry launched a platform for standardized medical data (medstandard.mohw.gov.tw), aiming to implement international health IT standards across all 23 medical centers within two years. This initiative is creating a unified medical data ecosystem and a regulatory environment that facilitates market entry for foreign firms

B Strong Policy Support for Biotech and Pharmaceuticals

The government supports biotech growth through the National Development Fund, venture capital, and R&D subsidies. Tax incentives under the Act for the Development of Biotech and Pharmaceutical Industry have been extended through 2031. These efforts support the expansion of CROs/CDMOs and encourage multinational firms to establish R&D centers in Taiwan. The industry is thriving, with projected output reaching NT$115 billion in 2025. New legislation—the Regenerative Medicine Act and Regenerative Medicinal Products Act—adds regulatory clarity and market momentum, positioning Taiwan as a regional hub for regenerative medicine, cell and gene therapy, and other high-value biomedical innovations.

C Cluster-Based Growth Across the Asia-Pacific

Taiwan has built end-to-end smart healthcare and pharmaceutical clusters in Hsinchu, Taichung, Tainan, and Kaohsiung, integrating ICT, AI, big data, and clinical resources into a unified R&D-to-market pipeline. Taiwanese firms are expanding into Southeast Asia with telehealth and minimally invasive medical solutions. Startups and manufacturers within these clusters benefit from faster clinical validation and tech transfer, creating ideal conditions for foreign R&D investment and licensing partnerships. These strengths reinforce Taiwan's role as a smart health hub in the Asia-Pacific.

D Sports Tech Innovation Opportunities

Taiwan's advanced ICT and AI capabilities, paired with strong OEM/ODM manufacturing, provide a solid foundation for developing smart sports equipment, wearables, and sensors. The government's Sports-Tech Integration Action Plan offers funding and pilot sites for smart venues, AI-driven training analytics, and cloud-based sports data services. Foreign firms can partner with local startups to build personalized sports data platforms, accelerate commercialization, and expand into Southeast Asia and global markets.

4 Investment Incentives

(A) Tax Incentives

To encourage foreign investment in Taiwan's biotech and pharmaceutical sector, support innovation, and promote industry-academia collaboration, the Act for the Development of Biotech and Pharmaceutical Industry offers tax incentives for companies engaged in the R&D and manufacturing of new drugs, novel formulations, high-risk medical devices, regenerative medicine, precision medicine, and digital health – whether for humans or animals and plants. Companies engaged in CDMO services for the above are also eligible, provided they are certified by the Ministry of Economic Affairs (MOEA) as a biotech and pharmaceutical company. Details of the incentives are listed below:

Table 1. Tax Incentives under the Act for the Development of Biotech and Pharmaceutical Industry

Incentive	Details
R&D	• Eligible companies may deduct up to 25% of their R&D expenditure from their profit-seeking enterprise income tax over a five-year period, with the annual deduction not exceeding 50% of the tax payable for that year (except in the final year, when the full remaining amount may be deducted).
Machinery, Equipment, or Systems	• For capital investments between NT$10 million and NT$1 billion in brand-new manufacturing machinery, equipment, or systems, companies may choose between: (1) 5% deduction over 1 year, or (2) 3% deduction over 3 years. The annual deduction cap is 30% of the company's profit-seeking enterprise income tax liability.
Corporate Shareholders	• Companies that invest in the establishment or expansion of an eligible biotech firm and remain a registered shareholder for at least 3 years may deduct up to 20% of the share acquisition cost from their income tax over a five-year period, with a yearly cap of 50% of the tax payable.
Individual Shareholders	• Individuals who invest NT$1 million or more in an unlisted biotech company that meets eligibility criteria and hold the shares for at least 3 years may deduct up to 50% of the investment amount from their total consolidated income starting in the third year, over a two-year period. The annual deduction cap is NT$5 million.
Senior Professionals or Technical Investors	• For shares acquired through employee incentives or technology investment (including shares purchased via stock warrants, even below par value), taxation may be deferred until actual transfer and based on the sale price. If the shareholder remains employed or continues providing technical services for 2 years, taxation may be based on the lower of the acquisition price or the transfer price.

Sources: MOEA Industrial Development Administration's 2024 Biotechnology Industry White Paper

In addition to the Act for the Development of Biotech and Pharmaceutical Industry, foreign investors in Taiwan may also be eligible for other tax incentives if they meet the relevant criteria. Details of the incentives are listed below:

Table 2. Additional Tax Incentives for the Biotech Industry

Incentive	Details
R&D Expenditure	• Companies may deduct up to 15% of qualified R&D expenditures from their profit-seeking enterprise income tax in the current year, or up to 10% spread evenly over three years.
Technology Licensing	• Royalties paid to foreign companies for imported technologies or products involving patents, copyrights, or other proprietary rights are exempt from profit-seeking enterprise income tax, subject to MOEA approval.
Equipment Procurement	• Companies or limited partnerships that invest NT$1 million–NT$2 billion in smart machinery, 5G systems, cybersecurity, AI, or energy-saving and carbon-reduction technologies may choose: (1) up to 5% of the expenditure deducted in the current year, or (2) up to 3% deducted over three years, with an annual cap of 30% of income tax payable. • Imported machinery which local manufacturers cannot produce are eligible for import tariff exemption.
Employee Stock Compensation	• Employees who hold company shares and remain employed for at least two years may be taxed based on the lower of the acquisition price or transfer price when the shares are sold.
Foreign Specialist Professional	• Qualified foreign professionals are exempt from income tax on 50% of annual salary income exceeding NT$3 million, which is not included in their consolidated taxable income.
Tax Incentives for Businesses in industrial parks	• Companies that move into technology industrial parks (TIP), science parks, and free trade zones (FTZ) are exempted from import tariffs, excise tax, and business tax on machinery and equipment, raw materials, fuel, supplies, and semi-finished products.
Miscellaneous Sources	• Companies or limited partnerships can reinvest their undistributed earnings within three years following the year they were generated. Provided that it meets a certain threshold, investments used for constructing or purchasing buildings, hardware, software, or technology for business operations, may be deducted from the current year's undistributed earnings, exempting them from the additional 5% profit-seeking enterprise income tax.

(B) Investment Incentives

Incentive	Details
Global Innovation Partnership Initiatives Program	• The program encourages multinational companies that complement Taiwanese industries to engage in R&D of forward-looking technologies, critical technologies required by the industry, or integrated technologies with Taiwanese companies to build Taiwan's industrial ecosystem. Collaboration can extend to startups and production activities for deeper value creation, achieving mutually beneficial outcomes. MOEA-approved companies can receive subsidies up to 50% of the total R&D expenses.
Taiwan Industry Innovation Platform Program	• To guide the industry towards high-value development and encourage companies to enter the high-end product application market to enhance the overall industry's added value rate, the MOEA Industrial Development Administration is promoting the Taiwan Industry Innovation Platform Program (TIIP), which provides thematic R&D project subsidies of 40-50% for companies with R&D teams in Taiwan and up to 40% subsidy for self-proposed R&D projects from enterprises.

5 Representative Taiwan Businesses

Pharmaceuticals

Bora Group

Bora Pharmaceuticals operates 10 internationally certified manufacturing facilities across Taiwan, Canada, and the United States, accredited by the FDA, Health Canada, MHRA, PIC/S GMP, and HACCP. Equipped with state-of-the-art technology, Bora offers fully customized CDMO services covering drug R&D, manufacturing, testing, regulatory approvals, registration, packaging, and global distribution. Its contract manufacturing and proprietary products are now marketed in over 100 countries across the Americas, Europe, Southeast Asia, and the Middle East, making Bora a key gateway for Taiwanese pharmaceutical formulations to enter global markets.

PharmaEssentia

Founded in 2003, PharmaEssentia is the first Taiwanese biotech company to independently develop a long-acting interferon drug and successfully enter major U.S. and European markets. Its flagship product, Ropeginterferon alfa-2b (Ropeg), is indicated for the treatment of polycythemia vera (PV). In addition to TFDA approval in Taiwan, the drug received marketing authorization from both the US FDA and the European EMA in 2019, making PharmaEssentia one of the few Asian companies to secure new drug approvals in G7 markets.

TaiMed Biologics

Founded in 2007, TaiMed is one of the few Taiwanese companies focused on immunotherapy and antiviral nucleic acid drug development. It has established comprehensive platforms for both antibody and nucleic acid therapies. The company is best known for its long-acting HIV antibody therapy, UB-421, which has completed Phase I and II clinical trials in multiple countries. The results demonstrated immune control comparable to HAART, and TaiMed is conducting cross-border clinical collaborations with the US NIH and Japanese research institutions.

Caliway Biopharmaceuticals

Founded in 2012, Caliway specializes in novel drug development for aesthetic medicine and chronic inflammatory diseases. The company is currently focused on developing two new drug candidates in the areas of localized fat reduction and weight management. In addition to R&D and clinical trials, Caliway is actively pursuing international partnerships for licensing and co-development opportunities with global pharmaceutical companies.

Biotechnology

TCI Co., Ltd

Established in 1980 and transitioned from ODM to CDMO in 2011, TCI leverages AI-driven innovation to provide clients with regulatory guidance, market strategies, full product lifecycle planning, and omnichannel supply chain management. With operations across Asia, Europe, and North America, its portfolio includes health supplements, facial masks, functional beverages, collagen products, skincare, and medical devices—all aligned with its mission to “join and improve consumers’ lives.”

Grape King Bio

Founded in 1969, Grape King Bio focuses on the production, manufacturing, and sales of health products. The company boasts a professional R&D team that develops health foods, energy drinks, and beverages suitable for all age groups. By keeping pace with market trends, Grape King Bio has established an integrated OEM/ODM platform with diverse dosage forms and contract manufacturing projects.

Smart Healthcare

Wistron Medical Technology

Founded in 2016 as a wholly owned subsidiary of Wistron Corporation, the company applies Wistron's decades of expertise in ICT product design and manufacturing to the medical device sector. It has accumulated strong development capabilities and project experience in life science instruments, in vitro diagnostics, medical imaging, exoskeleton systems, and smart hospital solutions.

SHENNOVA

Established in 2019, SHENNONA is the medical subsidiary of Compal Electronics. The company focuses on medical IoT solutions and the long-term operation of government healthcare projects. Its product lineup includes smart exercise carpets, AI-powered hearing aids, and handheld ultrasound devices. The handheld ultrasound has received Thai FDA approval, marking a major milestone in Compal's expansion into international smart healthcare markets.

EverFortune.AI (EFAI)

EverFortune.AI specializes in AI-driven medical imaging diagnostics. Its AI models for chest X-rays, mammography, intracranial hemorrhage, and nodule detection are undergoing TFDA Class II medical device review. The company collaborates with top-tier institutions such as Taipei Veterans General Hospital and National Taiwan University Hospital. Its platform supports integration with multiple AI models and hospital HIS/PACS systems, offering high clinical compatibility. Originating from National Taiwan University's medical and Taiwan AI Labs teams, EFAI combines medical statistics with deep tech, attracting investment and partnership interest from Japan, Hong Kong, and Singapore.

Medical Devices

PEGAVISION

Founded in 2009, PEGAVISION is a joint venture of Pegatron and KINSUS. The company specializes in the development, manufacturing, and sales of soft contact lenses and optical medical devices. It has independently developed new automated production lines and processes, and holds certifications including ISO 13485, GMP, Japan's PMDA, EU CE, Taiwan TFDA, China CFDA, and US FDA.

INTAI Technology Corp.

Established in 2004, INTAI began as a precision fastener manufacturer and has since evolved into a producer of high-end precision metal components. Now focused on medical device manufacturing, INTAI has extensive OEM experience with leading international medical brands and is a pioneer in producing key components for minimally invasive surgical instruments in Taiwan.

BenQ Medical

Founded in 1989, BenQ Medical is one of Taiwan's largest medical equipment manufacturers and a key player in BenQ AUO Group's entry into the healthcare industry. Its core businesses include surgical room equipment, single-use sterilized medical consumables, and hospital-specific engineering. BenQ Medical's products are certified under GMP, ISO 9001, ISO 13485, and CE standards and are exported to more than 50 countries worldwide.

Sports Technology

Johnson Health Tech

One of the world's top three fitness equipment manufacturers, Johnson Health Tech's Matrix brand is a preferred supplier for premium fitness centers worldwide. The company continues to digitize its equipment by integrating IoT modules, virtual coaching, course platforms, and cloud-based fitness data. It has also expanded into medical-grade rehabilitation equipment, targeting sports medicine and health insurance markets. Johnson collaborates with clients in the US, Germany, and Japan to develop connected fitness solutions, positioning itself as a brand-driven manufacturer at the intersection of sports tech and health data.

TROMIN TECH

Tromin Tech specializes in high-precision indoor positioning systems for sports science research, tactical team training, and intelligence systems. It provides real-time motion-sensing data to support coaches and trainers in pushing athletes to their full potential with measurable progress. The system supports a wide range of indoor and outdoor sports, including soccer, American football, field hockey, lacrosse, basketball, canoe polo, volleyball, and ice hockey.

OSENSE

In 2019, OSENSE launched its Sport AI solution, introducing Taiwan's first smart baseball strike zone system and AI-powered stadium management tools. The system enhances athletic training, player performance, real-time game decision-making, and venue operations. It has been adopted by the WBSC Premier12 tournament, the Chinese Professional Baseball League (CPBL), and school sports programs across Taiwan.

6 Landmark Foreign Investments

(A) Clinical Trial Development

1. Novartis (Switzerland)

As one of the world's largest pharmaceutical companies, Novartis consistently ranks among the top in R&D investment and now focuses exclusively on innovative drug development. In Taiwan, Novartis collaborates with leading medical centers including NTU Hospital (NTUH), Chang Gung Memorial Hospital, Mackay Memorial Hospital, and NCKU Hospital on clinical trials for treatments such as multiple sclerosis, cancer, and CAR-T cell therapy. The NTUH-Novartis Clinical R&D Center has completed over 100 studies, demonstrating a strong, long-term commitment to advancing pharmaceutical R&D in Taiwan.

2. AstraZeneca (UK)

Ranked among the world's top 20 pharmaceutical companies and a global leader in oncology drug development and manufacturing, AstraZeneca has maintained a presence in Taiwan for over 75 years and is dedicated to offering better treatment options to all patients. In 2025, it signed a memorandum of understanding with Taipei Veterans General Hospital to establish a strategic partnership focused on advancing Taiwan's role in clinical trial innovation.

(B) Manufacturing and Production

1. MINARIS Regenerative Medicine (Japan)

A global leader in regenerative medicine CDMO services, MINARIS partners with major pharmaceutical companies including GSK and SanBio. With seven production sites worldwide, it provides advanced medical services compliant with international GMP standards. In collaboration with Taiwan's Locus Cell, MINARIS is establishing a national-level PIS/GMP facility in the Hsinchu Biomedical Science Park, set to begin operations in 2026. The plant will be Asia's largest next-generation automated cell therapy production facility, strengthening Taiwan's role in the global regenerative medicine supply chain.

2. Sanofi (France)

As the world's fifth-largest pharmaceutical company, Sanofi focuses on R&D, manufacturing, and sales across key therapeutic areas including cardiovascular disease, thrombosis, oncology, diabetes, CNS disorders, internal medicine, and vaccines. In Taiwan, Sanofi has formed a strategic vaccine production partnership with Adimmune Corporation, with increasing annual supply volumes under a long-term manufacturing agreement.

3. Pluri Inc. (Israel)

A leading Israeli cell therapy company, Pluri specializes in placenta-derived regenerative products. In 2022, it partnered with ScinoPharm Taiwan to transfer its cell therapy technology to a new GTP/GMP-compliant production line in Southern Taiwan Science Park. Taiwan now serves as Pluri's Asian manufacturing and regulatory hub, underscoring the maturity of its CDMO capabilities and regulatory environment.

4. Viatris Inc. (US)

Viatris is a global leader in generics and biosimilars, serving patients in over 165 countries. It has partnered with Mycenax Biotech to co-develop and manufacture Trastuzumab, a biosimilar for breast cancer treatment. This marks the first time a US pharmaceutical company has leveraged Taiwan's CDMO capabilities to enter global markets, demonstrating the island's strengths in biologics manufacturing.

(C) Advancing Hardware-Software R&D and AI Collaboration

1. MERCK (Germany)

In response to Taiwan's growing biomedical innovation ecosystem, Merck established its M Lab™ Collaboration Center at the Taipei Bioinnovation Park. This is the first facility in Taiwan offering end-to-end biopharmaceutical process services, from preclinical testing to commercial-scale production. Leveraging Taiwan's dual strengths in biopharma and ICT, the center delivers smart, integrated solutions to enhance the resilience and competitiveness of the local biopharmaceutical sector.

2. Janssen Pharmaceuticals (US)

A subsidiary of Johnson & Johnson, Janssen develops and markets high-quality innovative drugs across oncology, immunology, infectious disease, psychiatry, and pulmonary hypertension. Through initiatives such as the Taiwan-Janssen Project, the company partners with ITRI and the Ministry of Economic Affairs to support local biotech startups by providing funding, mentoring, and global commercialization resources.

3. NEC Corporation (Japan)

As a leading Japanese IT and communications firm, NEC wields considerable influence in the field of ICT infrastructure. NEC has collaborated with Chang Gung medical group since 2021 to localize and enhance its AI health risk prediction models for chronic and cardiovascular conditions. This partnership positioned Taiwan as a key AI hub in NEC's Asia-wide health platform and designated Chang Gung Memorial Hospital as its flagship demonstration site in the Greater China region, deepening Taiwan–Japan collaboration in smart healthcare.

4. Peloton Interactive (US)

Founded in 2012 and headquartered in New York, Peloton is known for its smart fitness equipment and interactive streaming platform. Its products—such as sensor-integrated bikes and treadmills—use AI algorithms to deliver personalized coaching and community engagement. Since 2022, following the company's exit from in-house manufacturing, Peloton has expanded its partnership with Taiwan-based REXON Industrial, shifting full production of its Bike and Tread product lines to Taiwan.

Appendix

1. Numbeo
   https://www.numbeo.com/cost-of-living/

2. Ministry of Health and Welfare Official Website
   https://www.mohw.gov.tw/

3. National Sports Quarterly
   https://www.sa.gov.tw/Resource/Ebook/637989321823435422.pdf

4. Institute for Biotechnology and Medicine Industry (IBMI)
   https://ibmi.taiwan-healthcare.org/zh/

5. MOEA Department of Industrial Technology (DOIT) Official Site
   https://www.moea.gov.tw/MNS/doit/publication/Publication.aspx?menu_id=13400&pub_id=5981

6. National Biotechnology Research Park (NBRP) Official Site
   https://nbrp.sinica.edu.tw/

7. Taipei Bioinnovation Park
   https://tbip.com.tw/

8. Hsinchu Science Park Official Site
   https://www.sipa.gov.tw/

9. Central Taiwan Science Park Official Site
   https://www.ctsp.gov.tw/

10. Southern Taiwan Science Park Official Site
    https://www.stsp.gov.tw/

11. Global Bio & Investment Monthly
    https://news.gbimonthly.com/tw/magazine/show2.php?num=151

12. MOEA Industrial Development Administration's 2024 Biotechnology Industry White Paper
    https://www.biopharm.org.tw/images/2024/2024%20Biotechnology%20Industry%20in%20Taiwan.pdf

2025

Big Health

Key Industries in Taiwan

Department of Investment Promotion, MOEA

Address : 3F, No.82, Aiguo E. Rd., Zhongzheng District, Taipei City

Contact Number : +886-2-2389-2111

Fax : +886-2-2382-0497

Website : investtaiwan.nat.gov.tw

E-mail : dois@moea.gov.tw

InvesTaiwan

Address : 1F., No.82, Aiguo E. Rd., Zhongzheng District, Taipei City

Contact Number : +886-2-2311-2031

Fax : +886-2-2311-1949

Website : investtaiwan.nat.gov.tw

E-mail : service@invest.org.tw

Publisher : Department of Investment Promotion, MOEA